Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2249|181|3|385-400

ISSN： 0009-9104

Source： CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol.181, Iss.3, 2015-09, pp. : 385-400

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interpreting definitions: The problem of interpreting definitions of medical concepts

By Liss Per-Erik   Aspevall Olle   Karlsson Daniel   Forsum Urban  

Medicine, Health Care and Philosophy, Vol. 7, Iss. 2, 2004-01 ,pp. : 137-141

Springer Publishing Company

Access to resources Recommend Favorite

Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment

By  

Current Drug Safety, Vol. 5, Iss. 4, 2010-10 ,pp. : 293-307

Bentham Science Publishers

Access to resources Recommend Favorite

The Innovative Medicines Initiative: A European Response to the Innovation Challenge

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 91, Iss. 3, 2012-03 ,pp. : 418-425

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals

By  

Current Drug Safety, Vol. 5, Iss. 4, 2010-10 ,pp. : 287-292

Bentham Science Publishers

Access to resources Recommend Favorite

Accelerated Access to Innovative Medicines for Patients in Need

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 5, 2014-11 ,pp. : 559-571

John Wiley & Sons Inc

Access to resources Recommend Favorite